Skip to content

Optimal Single Dose Intrathecal Dexmedetomidine for Postoperative Analgesia

Optimal Single-dose Intrathecal Dexmedetomidine for Postoperative Analgesia After Lower Limb Surgery

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02660658
Enrollment
15
Registered
2016-01-21
Start date
2016-01-31
Completion date
2017-06-30
Last updated
2017-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lower Limb Surgery

Brief summary

Spinal anesthesia is a commonly used technique for lower limb surgeries offering better quality of postoperative analgesia, lower incidence of side effects, and shorter post-anesthesia care unit stay than general anesthesia. However, the relatively short duration of action of the currently available local anesthetics (LAs) make these advantages short-lived. The risk for local anesthetic toxicity (LAST) increases with the trials to use higher concentrations or volumes of intrathecal local anesthetics to increase the duration of analgesia. Dexmedetomidine has the potential to prolong the duration of perioperative analgesia without the need for using high doses of local anesthetics and hence with decreasing the potential risk of local anesthetic, but the increased likelihood adverse effects such as short term bradycardia and prolonged duration of motor block may offset these benefits.

Detailed description

The aim of this study is to determine the optimal single-dose of intrathecal dexmedetomidine that prolongs the analgesic duration with the least possible side effects. With the patients in the sitting position and the use of complete aseptic technique, 25G Whitacre spinal needles will be introduced through L2-L4 interspaces and after observing free flow of the CSF, a 3ml volume including bupivacaine 12.5mg in conjunction with dexmedetomidine (3 µg) will be injected in the first case, then the patient will be turned supine. The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance.

Interventions

The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* American Society of Anesthesiologists physical class I to II. * Patients scheduled for elective lower limb surgeries.

Exclusion criteria

* Morbid obese patients. * Severe or uncompensated cardiovascular disease. * Significant renal disease. * Significant hepatic disease. * Pregnancy. * Lactating . * Heart block. * Bradyarrhythmias. * Receiving adrenergic receptor antagonist medications. * Receiving calcium channel blockers. * Patients with pacemakers. * Patients with implanted cardioverter defibrillator. * Allergy to the study medications. * Psychological disease. * Neurological disorders. * Communication barrier. * Mental disorders. * Epilepsy. * Drug or alcohol abuse. * Contraindications to spinal anaesthesia. * Receiving opioid analgesic medications within 24 h before the operation.

Design outcomes

Primary

MeasureTime frameDescription
Duration of analgesiaFor 13 hours after surgeryThe duration of analgesia, defined as the time from administering of intrathecal study solution (T0) to the time for the first rescue analgesic request

Secondary

MeasureTime frameDescription
Onset of sensory blockadeFor 1 hour after initiaion of spinal anesthesiaOnset of sensory block time defined as the time elapsed from T0 to achieve the adequate sensory level for the planned surgery.
Onset of motor blockadeFor 2 hours after initiation of spinal anesthesiaOnset of motor block time defined as the time elapsed from T0 to achieve the Bromage scale of 3
Highest dermatome level of sensory blockadeFor 4 hours after initiation of spinal anesthesiaThe highest dermatome level of sensory blockade and the time needed to achieve this level from the time of injection as well as time to two segment sensory regression after T0 will be recorded
Time to motor regressionFor 6 hours after initiation of spinal anesthesiaTime to motor regression to a Bromage scale of 2
Sedation scoreFor 24 hours after initiation of spinal anesthesiaSedation scores will be assessed using a sedation scale (awake and alert= 0; quietly awake= 1; asleep but easily roused= 2; deep sleep= 3).
Postoperative nausea and vomitingFor 24 hours after initiation of spinal anesthesiaThe degree of nausea and vomiting. Nausea will be measured using a numerical rating system (none= 0; mild= 1; moderate= 2; severe= 3)
Postoperative pain scoreFor 24 hours after surgeryUsing visual analog scale
Intraoperative bradycardiaFor 4 hours after initiation of spinal anesthesia
Intraoperative use of ephedrineFor 4 hours after initiation of spinal anesthesia
Intraoperative use of atropineFor 4 hours after initiation of spinal anesthesia
Intraoperative use of supplemental fentanylFor 4 hours after initiation of spinal anesthesia
Intraoperative use of midazolamFor 4 hours after initiation of spinal anesthesia
Cumulative tramadol consumptionFor 24 hours after surgery

Countries

Egypt

Contacts

Primary ContactSamah Elkenany, MD
sk_20022000@yahoo.com00201002262557

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026